Aclaris Therapeutics, Inc. ACRS
3.50 USD +0.12 (+3.55%)
Regular-session close
3.50 0.00 0.00%
After hours · Nov 18, 4:25 PM ET
3.26 Day range 3.52
2.34 52-week range 6.60
- YTD
- +16.28%
- 1 year
- +40.56%
News
benzinga.com Canaccord Genuity Maintains Buy on Aclaris Therapeutics, Lowers Price Target to $12 Canaccord Genuity analyst Edward Nash maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Buy and lowers the price target from $13 to $12.
benzinga.com This Aclaris Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…
benzinga.com This Aclaris Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday Analysts downgraded SWK, SHLS, TSN, IDA and ACRS, with mixed price-target changes; ACRS saw the steepest cut, from $8 to $3.benzinga.com Wedbush Downgrades Aclaris Therapeutics to Neutral, Lowers Price Target to $3 Wedbush analyst Martin Fan downgrades Aclaris Therapeutics (NASDAQ:ACRS) from Outperform to Neutral and lowers the price target from $8 to $3.
benzinga.com Red Cat Downbeat Q3 Results, Joins Omeros, Deutsche Bank And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session U.S. stock futures fell as Red Cat plunged 25.8% after weak Q3 results and withdrawing FY26 guidance; several stocks also declined premarket.
benzinga.com Why is Aclaris Therapeutics Stock Trading Lower on Monday? Aclaris Therapeutics Inc. (NASDAQ:ACRS) CEO Neal Walker affirmed on Monday that the clinical-stage biopharmaceutical company will maintain its core development priorities despite missing primary and…
benzinga.com Why is Aclaris Therapeutics Stock Trading Lower on Monday? Aclaris Therapeutics misses Phase 2 bosakitug endpoints but launches its Phase 2b modzatinib trial for moderate-to-severe lichen planus.
benzinga.com Aclaris Therapeutics, Summit Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session U.S. stock futures were lower this morning, with the Nasdaq 100 futures falling over 1% on Monday.
benzinga.com Aclaris Therapeutics, Summit Therapeutics And Other Big Stocks Moving Lower In Monday’s Pre-Market Session U.S. stock futures fell as Aclaris plunged 21% after its dermatitis trial failed; Summit and other stocks also dropped in premarket trading.
benzinga.com Why Take-Two Interactive Software Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket Take-Two rose 4% ahead of GTA VI’s Nov. 19 release on strong presales. GreenPower led gainers, while Datavault AI plunged 43%.benzinga.com Aclaris Begins Phase 2b Modzatinib Trial In Lichen Planus, Fast Track-Designated Dual ITK/JAK3 Inhibitor With Potential As First Mechanistically Complete Oral Therapy - Dual Inhibition of ITK and JAK3 Provides Potential for Modzatinib to be the First Mechanistically Complete Oral Therapy for Lichen Planus, an Unaddressed Inflammatory Disease with No Approved…
benzinga.com Aclaris Phase 2 ADMIRATION Trial Of Anti-TSLP Antibody Bosakitug In Atopic Dermatitis Misses Primary Endpoint Of EASI Percent Change At Week 24, Secondary Endpoints Also Not Met - The ADMIRATION Trial Did Not Achieve its Primary Endpoint of Percent Change in Eczema Area and Severity Index (EASI) Score from Baseline at Week 24 -- Aclaris Remains Focused on Prioritizing the…
globenewswire.com Aclaris Therapeutics Initiates Phase 2b Trial of Modzatinib (ATI-2138) in Lichen Planus (LP) - Dual Inhibition of ITK and JAK3 Provides Potential for Modzatinib to be the First Mechanistically Complete Oral Therapy for Lichen Planus, an Unaddressed Inflammatory Disease with No Approved…
globenewswire.com Aclaris Therapeutics Announces Top Line Phase 2 Results for its Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) in Atopic Dermatitis (AD) - The ADMIRATION Trial Did Not Achieve its Primary Endpoint of Percent Change in Eczema Area and Severity Index (EASI) Score from Baseline at Week 24 - - Aclaris Remains Focused on Prioritizing the…
globenewswire.com Aclaris Therapeutics to Participate in the Jefferies Global Healthcare Conference WAYNE, Pa., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for…benzinga.com Aclaris Therapeutics Q3 EPS $(0.12) Beats $(0.16) Estimate, Sales $1.481M Beat $1.298M Estimate Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.16) by 25 percent. This is unchanged from the same period last year.…
benzinga.com Canaccord Genuity Maintains Buy on Aclaris Therapeutics, Raises Price Target to $13 Canaccord Genuity analyst Edward Nash maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Buy and raises the price target from $10 to $13.
benzinga.com Wedbush Maintains Outperform on Aclaris Therapeutics, Lowers Price Target to $8 Wedbush analyst Martin Fan maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Outperform and lowers the price target from $10 to $8.
benzinga.com HC Wainwright & Co. Reiterates Buy on Aclaris Therapeutics, Maintains $16 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aclaris Therapeutics (NASDAQ:ACRS) with a Buy and maintains $16 price target.
benzinga.com Aclaris Says Early Data Validates Dual-Target Approach for Eczema, Asthma Drug Aclaris Therapeutics announces positive Phase 1b trial data for ATI-052 in eczema and asthma alongside a $50 million public financing round.
benzinga.com Whirlpool Posts Downbeat Q3 Results, Joins HSBC, Hilton Hotels And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session U.S. futures rose, but Whirlpool plunged after a major earnings miss and lowered guidance; HSBC, Armstrong World and others also fell premarket.benzinga.com Aclaris Therapeutics Prices $50M Offering Of 7,785,714 Shares And Warrants To Purchase 6.5M Shares At $3.50/Unit Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced the pricing of an…
